Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the activity of 2 different doses of PF-06273340 on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants

NCT06077786

Healthy Participants

COMPLETED PHASE1

Exploratory Study to Investigate Cognition Function and Mobility in Individuals With Pain

NCT02974114

Pain

TERMINATED PHASE4

Can Training Increase Reporting Accuracy and Study Power in Human Pain Trials

NCT03952715

Healthy Placebo Response

UNKNOWN NA

Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft

NCT05919745

Pain, Post Operative Quality of Life

RECRUITING PHASE4

Ibuprofen With or Without Acetaminophen for Low Back Pain

NCT03554018

Low Back Pain

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

PF-06273340

Intervention Type DRUG

PF-06273340 50 mg

2

Group Type EXPERIMENTAL

PF-06273340

Intervention Type DRUG

PF-06273340 400 mg

3

Group Type ACTIVE_COMPARATOR

Pregabalin

Intervention Type DRUG

Pregabalin 300 mg

4

Group Type ACTIVE_COMPARATOR

Ibuprofen

Intervention Type DRUG

Ibuprofen 600 mg

5

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-06273340

PF-06273340 50 mg

Intervention Type DRUG

PF-06273340

PF-06273340 400 mg

Intervention Type DRUG

Pregabalin

Pregabalin 300 mg

Intervention Type DRUG

Ibuprofen

Ibuprofen 600 mg

Intervention Type DRUG

Placebo

Matching Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).
* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
* Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
* Any condition possibly affecting drug absorption (eg, gastrectomy).
* A positive urine drug screen

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes